Schreiber S
1st Department of Medicine, Christian-Albrechts University, Kiel, Germany.
Hepatogastroenterology. 2000 Jan-Feb;47(31):15-28.
The past decade has been characterized by an enormous progress in the understanding of the pathophysiology of chronic intestinal inflammation. Novel drugs, which include tumor necrosis factor alpha binding proteins (i.e., the monoclonal antibody infliximab), have been introduced into the therapeutic management of Crohn's disease. With our increasing knowledge of disease pathophysiology and the identification of key mediators, it is to be expected that the efficacy of anti-inflammatory therapy will further increase. The exploration of the genetic etiology of inflammatory bowel disease holds great future promises.
过去十年的特点是在慢性肠道炎症病理生理学的理解方面取得了巨大进展。新型药物，包括肿瘤坏死因子α结合蛋白（即单克隆抗体英夫利昔单抗），已被引入克罗恩病的治疗管理中。随着我们对疾病病理生理学的了解不断增加以及关键介质的确定，可以预期抗炎治疗的疗效将进一步提高。对炎症性肠病遗传病因的探索有着巨大的未来前景。
